{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["nivolumab"],["nivolumab","ipilimumab"]],"indication":"cisplatin-ineligible muscle-invasive bladder cancer","name":"CA209-9DJ","nct_id":"NCT03520491","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ca209-9dj-nct03520491. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Nivolumab 3 mg/kg on day 1 of each cycle for a total of 5 cycles. Each cycle will be two weeks long and treatment will occur during weeks 0, 2, 4, 6, and 8.","label":"Cohort 1","type":"EXPERIMENTAL"},{"description":"Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1 of each cycle, followed by Nivolumab 3 mg/kg on day 22 of each cycle for a total of 2 cycles. Each cycle will be six weeks long. Ipilimumab and Nivolumab will occur on weeks 0 and 6 while Nivolumab alone will occur on weeks 3 and 9.","label":"Cohort 2","type":"EXPERIMENTAL"},{"description":"Ipilimumab 3 mg/kg on day 1 each cycle and Nivolumab 1 mg/kg on day 1 of each cycle for a total of 3 cycles. Each cycle will be three weeks long and treatment will occur during weeks 0, 3, and 6.","label":"Cohort 3","type":"EXPERIMENTAL"},{"description":"Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1, of each cycle, followed by Nivolumab 3 mg/kg on day 22 and Ipilimumab 3mg/kg and Nivolumab 1mg/kg on day 45.","label":"Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-01","type":"ESTIMATED"},"conditions":["Bladder Cancer"],"enrollment":{"count":52,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":[],"type":"DRUG"},{"name":"Ipilimumab","otherNames":[],"type":"DRUG"},{"name":"Radical cystectomy","otherNames":[],"type":"PROCEDURE"}],"last_update":"2026-02-17","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"number of patients who proceed to radical cystectomy and pelvic lymph node dissection (RC-PLND)","timeFrame":"within 60 days after completion of neoadjuvant nivolumab or nivolumab in combination with ipilimumab for cisplatin-ineligible MIBC, without delays due to treatment-related toxicities or progressive disease"}],"references":[{"citation":"Giannakodimos I, Ziogou A, Giannakodimos A, Tzelepis K, Kratiras Z, Fragkiadis E, Zachos I, Tzortzis V, Chrisofos M, Charalampakis N. Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update. Immunotherapy. 2025 Apr;17(6):447-455. doi: 10.1080/1750743X.2025.2501929. Epub 2025 May 6.","pmid":"40329651","type":"DERIVED"}],"start_date":{"date":"2018-04-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy","url":"https://clinicaltrials.gov/study/NCT03520491"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ca209-9dj-nct03520491"}